|
|
Am. J. Biomed. Sci. 2015, 7(1), 1-8; doi: 10.5099/aj150100001 |
Enhancement of Bone Marrow CD41+ Megakaryocytes as well as Modulation of TNF-α, IL-12, and IL-5 by a Novel Small Molecule, UTL-5g, in Mice Treated with Cisplatin |
Frederick
Valeriote1, Ben Chen2, Joseph Media1, Kevin R.
Bobbitt3, Jiajiu Shaw2* |
1 Department of Internal Medicine, Henry Ford Health
System, Detroit, Michigan 48202 |
2 21st Century Therapeutics, Inc., Detroit,
Michigan 48202 |
3 Department of Public Health Sciences, Henry Ford
Health System, Detroit, Michigan 48202 |
*Corresponding
author |
Dr. Jiajiu Shaw |
21st
Century Therapeutics, Inc. |
440 Burroughs
St., Suite 447 |
Detroit, MI
48202 |
USA |
Tel: (7348) 330-6052 |
E-mail: jiajiushaw@gmail.com |
liwei.gao@ncich.com.cn (Liwei Gao) |
Abstract UTL-5g is a novel small-molecule chemoprotective agent against cisplatin-induced host cytotoxicity. Recent studies showed that UTL-5g increased the blood platelet count, which was reduced in cisplatin-treated mice. In order to have a better understanding about the mechanism of action by which UTL-5g promotes platelet production, BDF1 mice were treated with or without UTL-5g after cisplatin treatment; several hematological analyses were conducted. The results showed that treatment of mice with UTL-5g alone by either i.p. injection or oral gavage markedly increased platelet counts. UTL-5g also restored bone marrow cell counts that were reduced by cisplatin treatment. Flow cytometric analysis showed that bone marrow CD41+ megakaryocytic cells were significantly increased in animals pretreated with UTL-5g before cisplatin. Measurement of secreted cytokines showed that pretreatment of UTL-5g lowered blood levels of both TNF-a and IL-12 (p70) elevated by cisplatin treatment. On the other hand, pretreatment of UTL-5g raised blood levels of IL-5 that were lowered by cisplatin treatment. The results also showed that 60 mg/kg is the optimal dose of UTL-5g by oral route for the protection of bone marrow cells, CD41+ megakaryocytes, and platelets. In conclusion, this study suggests that UTL-5g (by i.p. injection or oral gavage) enhances the production of platelets by either protecting or increasing bone marrow CD41+ megakaryocytic cells at least in part; UTL-5g also modulates TNF-a, IL-12 (p70), and IL-5. Taken together, these observed effects of UTL-5g on megakaryocytes and cytokines play important roles in the chemoprotective properties of UTL-5g. Keywords: chemoprotective agent, cisplatin, platelets, CD41+ megakaryocytes,
bone marrow cells Download the full article (PDF)
|
Publisher | Missions and Scope | Editorial Board | Instructions for Authors |
© American Journal of Biomedical Sciences 2007-2021. All Rights Reserved. |